MNOV - MediciNova, Inc. Summary, Stock Quote and News

10.31 -0.47 (-4.36%)

After Hours 10.31 (%)

Data as of Oct 20, 2018

Prev. Close 10.78
Price Open 10.68
Volume 130,258
Day's Range 10.25 - 10.73
52 Wk Range 5.81 - 14.5
50 Day Moving Avg. 11.11
PE Ratio 0
Shares Outstanding 41.88M
Market Cap 431.77M

Trade MNOV stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
3/28/18	B. Riley FBR	Initiates Coverage On	Buy	22.0
8/27/12	McNicoll Lewis Vlak	Terminates
5/24/12	Ladenburg Thalmann	Maintains	Buy	10.5

The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker Shanthi RexalineFri, 05 Oct 2018 08:35:11 -0400
MediciNova Announces FDA Orphan Drug Designation to MN-166 for Glioblastoma Charles GrossFri, 05 Oct 2018 04:27:05 -0400
MediciNova Late Tuesday Reported FDA Feedback Regarding Phase 3 Plan For MN-166 (ibudilast) In ALS; FDA Said If A Single Trial Shows Statistically Significant Benefit, Additional Trial May Not Be Necessary Benzinga_NewsdeskWed, 26 Sep 2018 07:59:38 -0400
MediciNova Announces Publication Of Results Of SPRINT-MS Phase 2b Trial Of MN-166 (ibudilast) In Progressive MS In New England Journal Of Medicine Benzinga_NewsdeskWed, 29 Aug 2018 17:03:25 -0400
44 Biggest Movers From Friday Lisa LevinMon, 27 Aug 2018 04:34:17 -0400
40 Stocks Moving In Friday's Mid-Day Session Lisa LevinFri, 24 Aug 2018 12:47:09 -0400
National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova's MN-166 (ibudilast) in Alcohol Use Disorder Charles GrossTue, 21 Aug 2018 04:04:48 -0400
MediciNova Late Monday Announced Initiation Of NIHR Grant-Funded Phase 2/3 Trial Of MN-166 (ibudilast) For Degenerative Cervical Myelopathy In Collaboration With University Of Cambridge Benzinga NewsdeskTue, 07 Aug 2018 09:05:39 -0400
MediciNova Announces MN-166 ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK Charles GrossWed, 01 Aug 2018 03:53:00 -0400
MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial Charles GrossSun, 29 Jul 2018 20:17:59 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma Globe NewswireOct 04, 2018
MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS Globe NewswireSep 25, 2018
MediciNova to Present at the Ladenburg Thalmann 2018 Healthcare Conference in New York Globe NewswireSep 18, 2018
MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York Globe NewswireSep 04, 2018
MediciNova Announces the Publication of Results of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS in the New England Journal of Medicine Globe NewswireAug 29, 2018
National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova's MN-166 (ibudilast) in Alcohol Use Disorder Globe NewswireAug 20, 2018
Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software — New Horizons, Emerging Trends, and Upcoming Developments Globe NewswireAug 20, 2018
MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge Globe NewswireAug 06, 2018
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK Globe NewswireJul 31, 2018
MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial Globe NewswireJul 29, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

FDA grants Orphan Drug designation to MediciNova's MN-166 for glioblastoma Seeking AlphaOct 05, 2018
MediciNova up 2% premarket on potential approval path for MN-166 in ALS Seeking AlphaSep 26, 2018
MediciNova Announces Positive FDA Feedback Regarding Phase ' Plan for MN-–66 (ibudilast) in ALS GuruFocusSep 25, 2018
Week 39 Breakout Forecast: Short-Term Picks To Give You An Edge Seeking AlphaSep 24, 2018
MediciNova to Present at the Ladenburg Thalmann —…–8 Healthcare Conference in New York GuruFocusSep 18, 2018
Week 38 Breakout Forecast: Short-Term Picks To Give You An Edge Seeking AlphaSep 17, 2018
Week 37 Breakout Forecast: Short-Term Picks To Give You An Edge Seeking AlphaSep 09, 2018
Week 36 Breakout Forecast: Short-Term Picks To Give You An Edge Seeking AlphaSep 01, 2018
Your Daily Pharma Scoop: Karyopharm Buoyed, MediNova Succeeds, Ardelyx's Publication Seeking AlphaAug 31, 2018
MediciNova Announces the Publication of Results of the SPRINT-MS Phase —b Trial of MN-–66 ... GuruFocusAug 29, 2018
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q2 2018	EST	Actual	Surprise
EPS:	-0.11	-0.08	0.03
Rev:		0.00

Q3 2018	EST	Actual	Surprise
EPS:	-0.11	Expected 2018-10-26
Rev:		Expected 2018-10-26

Company Profile

Brokerage Center

Compare All Online Brokerages

Market Overview

MediciNova, Inc. MNOV:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

MediciNova, Inc. MNOV:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners